关于余甘子的全球研究趋势: 1993年至2024年的文献计量与可视化分析

doi:10.5246/jcps.2026.02.013

中国药学(英文版) ›› 2026, Vol. 35 ›› Issue (2): 173-186.DOI: 10.5246/jcps.2026.02.013

关于余甘子的全球研究趋势: 1993年至2024年的文献计量与可视化分析

邱秀梁¹, 蓝荫香²^,^*()

^1. 福建医科大学肿瘤临床医学院, 福建省肿瘤医院药剂科, 福建福州 350014
^2. 福建省儿童医院药剂科(上海儿童医学中心福建医院) 福建医科大学妇儿临床医学院, 福建福州 350000

收稿日期:2025-09-10 修回日期:2025-11-04 接受日期:2025-11-12 出版日期:2026-03-05 发布日期:2026-03-05
通讯作者: 蓝荫香

Global research trends on Phyllanthus emblica: a bibliometric and visual analysis from 1993 to 2024

Xiuliang Qiu¹, Yinxiang Lan²^,^*()

^1. Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, Fujian, China
^2. Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350000, Fujian, China

Received:2025-09-10 Revised:2025-11-04 Accepted:2025-11-12 Online:2026-03-05 Published:2026-03-05
Contact: Yinxiang Lan
Supported by:
Startup Fund for Scientific Research, Fujian Medical University (Grant No. 2022QH1216).

摘要/Abstract

摘要：

余甘子是一种传统的药用和食用植物, 20世纪90年代以来对其研究再度受到人们的关注。本研究旨在对余甘子进行全面的文献计量分析, 揭示近年来余甘子研究的热点和趋势。采用关键词在Web of Science Core Collection (WOSCC)数据库中进行检索, 使用CiteSpace和VOSviewer进行分析。共纳入1993年至2024年间发表的860篇文献, 这些文献由来自59个国家1068个机构的3402位作者发表在363种期刊上。印度发表的文献数量最多, 中国科学院是发表文献数量最多的机构。Yingjun Zhang和Chongren Yang是主要作者, 《民族药理学杂志》是发表文献最多的期刊。关键词分析表明, 该领域的研究趋势集中在抗氧化活性、提取物、药用植物、酸和细胞凋亡等。本研究对1993年至2024年全球余甘子的研究进行了有价值的分析, 可能为进一步研究提供关键方向。

关键词: 余甘子, 文献计量学, CiteSpace, VOSviewer, 研究趋势

Abstract:

Phyllanthus emblica, renowned for its medicinal and edible properties, has attracted increasing scholarly attention since the 1990s. The present study sought to deliver a comprehensive bibliometric analysis and elucidate the emerging research hotspots on P. emblica over the period 1993–2024. A systematic search of the Web of Science Core Collection (WOSCC) was conducted using relevant keywords, and bibliometric mapping was performed using CiteSpace and VOSviewer. A total of 860 publications were identified, spanning 363 journals, authored by 3402 researchers from 1068 institutions across 59 countries. India accounted for the highest number of publications, whereas the Chinese Academy of Sciences emerged as the most prolific institution. Yingjun Zhang and Chongren Yang were recognized as the leading contributor, and the Journal of Ethnopharmacology ranked first in publication volume. Keyword co-occurrence analysis indicated that current research predominantly centered on antioxidants, bioactive extracts, kinetics, antibacterial activity, tannins, phenolic compounds, acids, compound characterization, and apoptosis. This study offered a thorough global perspective on P. emblica research over the past three decades and provided strategic insights to inform and inspire future investigations.

Key words: Phyllanthus emblica, Bibliometric analysis, CiteSpace, VOSviewer, Research trends

Supporting:

邱秀梁, 蓝荫香. 关于余甘子的全球研究趋势: 1993年至2024年的文献计量与可视化分析[J]. 中国药学(英文版), 2026, 35(2): 173-186.

Xiuliang Qiu, Yinxiang Lan. Global research trends on Phyllanthus emblica: a bibliometric and visual analysis from 1993 to 2024[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(2): 173-186.

图/表 16

Figure 1. Flow chart of the literature search and screening procedures.

Figure 2. Distribution of publications.

Table 1. The top nine most productive countries.

Table 2. The top 10 productive organizations.

Figure 3. (A) The country collaboration network (Top 30); (B) Institution co-occurrence map.

Table 3. The top 10 authors by number of publications.

Figure 4. Distribution of authors. (A) The network map of the authors; (B) The network of co-cited authors.

Table 4. The top 10 citation journals.

Figure 5. Visualization of journals. (A) The network map of cited journals; (B) The network of co-cited journals.

Table 5. The top five co-citation journals.

Figure 6. Network cluster of co-cited literature.

Table 6. The top 22 keywords co-occurrence.

Figure 7. Keyword co-occurrence map.

Figure 8. Visualization of keywords burst (32 keywords).

Figure 9. Keyword cluster analysis.

Figure 10. Timeline view of keyword clusters.

参考文献 40

[1]	Yadav, S.S.; Singh, M.K.; Singh, P.K.; Kumar, V. Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomed. Pharmacother. 2017, 93, 1292–1302.
[2]	Nashine, S.; Kanodia, R.; Nesburn, A.B.; Soman, G.; Kuppermann, B.D.; Kenney, M.C. Nutraceutical effects of Emblica officinalis in age-related macular degeneration. Aging. 2019, 11, 1177–1188.
[3]	Hazarika, T.K.; Ningombam, L.; Debbarma, P.; Momin, M.D.; Lalrinzuala, P.; Devi, L.S. Genetic diversity analysis of Phyllanthus acidus Skeels of north-east India: Insights from multivariate analysis. Sci. Rep. 2025, 15, 6647.
[4]	Wu, M.; Liu, M.; Wang, F.Y.; Cai, J.H.; Luo, Q.Y.; Li, S.S.; Zhu, J.X.; Tang, Z.Z.; Fang, Z.F.; Wang, C.X.; Chen, H. The inhibition mechanism of polyphenols from Phyllanthus emblica Linn. fruit on acetylcholinesterase: A interaction, kinetic, spectroscopic, and molecular simulation study. Food Res. Int. 2022, 158, 111497.
[5]	Wu, M.; Cai, J.H.; Fang, Z.F.; Li, S.S.; Huang, Z.Q.; Tang, Z.Z.; Luo, Q.Y.; Chen, H. The composition and anti-aging activities of polyphenol extract from Phyllanthus emblica L. fruit. Nutrients. 2022, 14, 857.
[6]	Duan, X.Y.; Lin, L.Z.; Zhao, M.M. Hydrolyzable tannins and pectin are glycolipid lowering ingredients in Phyllanthus emblica Linn.: Valid interaction with gut action targets. Food Chem. 2025, 463, 141313.
[7]	Prananda, A.T.; Dalimunthe, A.; Harahap, U.; Simanjuntak, Y.; Peronika, E.; Karosekali, N.E.; Hasibuan, P.A.Z.; Syahputra, R.A.; Situmorang, P.C.; Nurkolis, F. Phyllanthus emblica: A comprehensive review of its phytochemical composition and pharmacological properties. Front. Pharmacol. 2023, 14, 1288618.
[8]	Hu, Q.; Wang, S.K.; Cheng, R.Y.; Liu, Y.Q.; Chang, Z.H.; Huang, Y.; Chen, Y.X.; Luo, X.W.; Zhou, L.P.; Wang, B.J.; Gao, Y.; Chen, H.J.; Liu, R.P.; Zhang, L.Z. Tannins in Phyllanthus emblica L. improves cisplatin efficacy in lung cancer cells by boosting endoplasmic reticulum stress to trigger immunogenic cell death. Phytomedicine. 2024, 123, 155219.
[9]	Suvandee, W.; Teeranachaideekul, V.; Jeenduang, N.; Nooeaid, P.; Makarasen, A.; Chuenchom, L.; Techasakul, S.; Dechtrirat, D. One-pot and green preparation of Phyllanthus emblica extract/silver nanoparticles/polyvinylpyrrolidone spray-on dressing. Polymers. 2022, 14, 2205.
[10]	Wang, R.B.; Xu, X.Y.; Puja, A.M.; Perumalsamy, H.; Balusamy, S.R.; Kim, H.; Kim, Y.J. Gold nanoparticles prepared with Phyllanthus emblica fruit extract and bifidobacterium animalis subsp. lactis can induce apoptosis via mitochondrial impairment with inhibition of autophagy in the human gastric carcinoma cell line AGS. Nanomaterials. 2021, 11, 1260.
[11]	Liu, X.L.; Cui, C.; Zhao, M.M.; Wang, J.S.; Luo, W.; Yang, B.; Jiang, Y.M. Identification of phenolics in the fruit of emblica (Phyllanthus emblica L.) and their antioxidant activities. Food Chem. 2008, 109, 909–915.
[12]	Lin, H.Y.; Lin, C.H.; Kuo, Y.H.; Shih, C.C. Antidiabetic and antihyperlipidemic activities and molecular mechanisms of Phyllanthus emblica L. extract in mice on a high-fat diet. Curr. Issues Mol. Biol. 2024, 46, 10492–10529.
[13]	Sharif, M.A.; Khan, A.M.; Salekeen, R.; Rahman, M.H.; Mahmud, S.; Bibi, S.; Biswas, P.; Hasan, M.N.; Islam, K.M.D.; Mahbubur Rahman, S.M.; Islam, M.E.; Alshammari, A.; Alharbi, M.; Hayee, A. Phyllanthus emblica (Amla) methanolic extract regulates multiple checkpoints in 15-lipoxygenase mediated inflammopathies: Computational simulation and in vitro evidence. Saudi Pharm. J. 2023, 31, 101681.
[14]	Varnasseri, M.; Siahpoosh, A.; Hoseinynejad, K.; Amini, F.; Karamian, M.; Yad, M.J.Y.; Cheraghian, B.; Khosravi, A.D. The effects of add-on therapy of Phyllanthus emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial. Complementary Ther. Med. 2022, 65, 102808.
[15]	Chen, J.D.; Chen, S.Y.; Liao, C.C.; Fang, C.Y.; Yen, G.C. Enhancing cognitive memory function using Phyllanthus emblica polysaccharides via modulating autophagy and reshaping the gut microbiota. Food Funct. 2025, 16, 8140–8159.
[16]	Li, G.F.; Yu, Q.; Li, M.Q.; Zhang, D.K.; Yu, J.; Yu, X.H.; Xia, C.X.; Lin, J.Z.; Han, L.; Huang, H.Z. Phyllanthus emblica fruits: a polyphenol-rich fruit with potential benefits for oral management. Food Funct. 2023, 14, 7738–7759.
[17]	Saifulazmi, N.F.; Rohani, E.R.; Harun, S.; Bunawan, H.; Hamezah, H.S.; Nor Muhammad, N.A.; Azizan, K.A.; Ahmed, Q.U.; Fakurazi, S.; Mediani, A.; Sarian, M.N. A review with updated perspectives on the antiviral potentials of traditional medicinal plants and their prospects in antiviral therapy. Life. 2022, 12, 1287.
[18]	Huang, S.Q.; Li, S.L.; Li, G.Y.; Wang, C.Y.; Guo, X.H.; Zhang, J.; Liu, J.; Xu, Y.; Wang, Y.C. Fabrication and characterization of Phyllanthus emblica extract-polyvinyl alcohol/carboxymethyl cellulose sodium antioxidant hydrogel and its application in wound healing. Pharmaceutics. 2024, 16, 1531.
[19]	Avinash, P.G.; Hamid, Shams, R.; Dash, K.K.; Shaikh, A.M.; Ungai, D.; Harsányi, E.; Suthar, T.; Kovács, B. Recent insights into the morphological, nutritional and phytochemical properties of Indian gooseberry (Phyllanthus emblica) for the development of functional foods. Plants. 2024, 13, 574.
[20]	Zhang, Y.; Lu, L.S.; Zheng, R. Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis. Front. Pharmacol. 2023, 14, 1140771.
[21]	Zhang, M.; Kou, L.; Qin, Y.Y.; Chen, J.W.; Bai, D.Z.; Zhao, L.; Lin, H.Y.; Jiang, G.H. A bibliometric analysis of the recent advances in diazepam from 2012 to 2021. Front. Pharmacol. 2022, 13, 1042594.
[22]	Wang, Y.; Lu, X.J.; Yue, X.F.; Kan, L.W.; Du, S.Z. Bibliometric analysis of PCSK9 inhibitors for cardiovascular diseasemanagement based on Web of Science. J. Chin. Pharm. Sci. 2025, 34, 232–250.
[23]	Li, B.X.; Wu, T.; Dong, M.F.; Ye, K.; Wang, J.; Ren, C.D. Immunotherapy research for prostate cancer from 2000 to 2024: A bibliometric and visualization analysis. Transl. Androl. Urol. 2025, 14, 3064–3087.
[24]	Wang, Y.; Rao, Y.F.; Lin, Z.J.; Sa, R.N.; Yin, Y.L.; Zhang, X.M.; Zhang, B. Current status and trends of research on anthracycline-induced cardiotoxicity from 2002 to 2021: A twenty-year bibliometric and visualization analysis. Oxid. Med. Cell. Longev. 2022, 2022, 6260243.
[25]	Lan, Y.X.; Qiu, X.L.; Huang, D.D. Bibliometric and visual analysis of global research on snake venom disintegrins (2009–2023). J. Chin. Pharm.Sci. 2024, 33, 1012–1024.
[26]	Sabe, M.; Chen, C.M.; Perez, N.; Solmi, M.; Mucci, A.; Galderisi, S.; Strauss, G.P.; Kaiser, S. Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. Neurosci. Biobehav. Rev. 2023, 144, 104979.
[27]	Ling, L.X.; Ouyang, Y.B.; Hu, Y. Research trends on nanomaterials in gastric cancer: A bibliometric analysis from 2004 to 2023. J. Nanobiotechnol. 2023, 21, 248.
[28]	Zhao, J.; Liao, B.; Gong, L.; Yang, H.Y.; Li, S.; Li, Y.S. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis. Hum. Vaccines Immunother. 2023, 19, 2254262.
[29]	Yu, Z.Y.; Xie, L.; Zhang, J.; Lin, H.; Niu, T. The evolution of minimal residual disease: Key insights based on a bibliometric visualization analysis from 2002 to 2022. Front. Oncol. 2023, 13, 1186198.
[30]	Ran, Y.H.; Fan, Y.Y.; Yang, G.; Li, P.Y.; Zhang, Y.J.; Xu, T.F.; Zheng, X.; Wei, T. Frontiers and hotspots evolution in robot-assisted thyroidectomy: A bibliometric analysis from 2008 to 2023. Gland Surg. 2025, 14, 1923–1936.
[31]	Zhang, Y.; Liu, X.Y.; Qiao, X.F.; Fan, Y.B. Characteristics and emerging trends in research on rehabilitation robots from 2001 to 2020: Bibliometric study. J. Med. Internet Res. 2023, 25, e42901.
[32]	Guo, Y.; Zhang, H.Q.; Yu, X.Q. A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022. Front. Pharmacol. 2023, 14, 1200193.
[33]	Yang, X.L.; Yin, H.; Zhang, D.Y.; Peng, L.S.; Li, K.L.; Cui, F.; Xia, C.C.; Li, Z.S.; Huang, H.J. Bibliometric analysis of cathepsin B research from 2011 to 2021. Front. Med. 2022, 9, 898455.
[34]	Gulati, R.; Agarwal, S.; Agrawal, S. Hepatoprotective studies on Phyllanthus emblica Linn. and quercetin. Indian J. Expl. Biol. 1995, 33, 261–268.
[35]	Murugesan, S.; Kottekad, S.; Crasta, I.; Sreevathsan, S.; Usharani, D.; Perumal, M.K.; Mudliar, S.N. Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants–Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy)–A molecular docking and simulation study. Comput. Biol. Med. 2021, 136, 104683.
[36]	Begum, M.A.; Hossain, R.; Jain, D.; Murti, Y.; Agrawal, K.K.; Janmeda, P.; Neto, I.C.P.; Coutinho, H.D.M.; Raposo, A.; Saraiva, A.; Han, H.; Romão, B.; Lisboa, P.; Moreira, P.; Islam, M.T. Recent insights into the antimicrobial properties of Phyllanthus emblica L.: A comprehensive review of wonder berry. Chem. Biodivers. 2024, 21, e202400747.
[37]	Hegde, S.N.; Lavanya Devi, K.; Choudhary, M.; Menon, N.; Singh, G. A comprehensive metabolome profiling of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica to explore the medicinal potential of Triphala. Sci. Rep. 2024, 14, 31635.
[38]	Zhang, L.M.; Yuan, J.M.; Pu, T.L.; Qu, W.L.; Lei, X.; Ma, K.H.; Qian, K.J.; Zhao, Q.L.; Liao, C.F.; Jin, J. Chromosome-scale genome assembly of Phyllanthus emblica L. ‘Yingyu’. DNA Res. 2025, 32, dsaf006.
[39]	Tiwana, G.; Cock, I.E.; Cheesman, M.J. Phyllanthus emblica: phytochemistry, antimicrobial potential with antibiotic enhancement, and toxicity insights. Microorganisms. 2025, 13, 611.
[40]	Saini, R.; Kumar, V.; Patel, C.N.; Sourirajan, A.; Dev, K. Synergistic antibacterial activity of Phyllanthus emblica fruits and its phytocompounds with ampicillin: A computational and experimental study. Naunyn Schmiedeberg’s Arch. Pharmacol. 2024, 397, 857–871.

关于余甘子的全球研究趋势: 1993年至2024年的文献计量与可视化分析

Global research trends on Phyllanthus emblica: a bibliometric and visual analysis from 1993 to 2024

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 16

参考文献 40

相关文章 6

编辑推荐

Metrics

本文评价

[1]	符青雷, 胡贝贝, 吴春兴. 用药咨询的研究现状及趋势: 基于文献计量学研究[J]. 中国药学(英文版), 2025, 34(4): 354-369.
[2]	王雨, 卢晓静, 岳向峰, 阚琳玮, 杜书章. 基于Web of Science的PCSK9抑制剂在心血管治疗领域相关研究文献计量学分析[J]. 中国药学(英文版), 2025, 34(3): 232-250.
[3]	卢晓静, 贾雪冬, 司方莹, 杨晰, 张婉, 尹钊. 药师主导的老年患者干预研究: 一项文献计量学分析[J]. 中国药学(英文版), 2024, 33(8): 751-765.
[4]	蓝荫香, 邱秀梁, 黄丹丹. 2009–2023年世界范围内蛇毒解离素的文献计量学研究[J]. 中国药学(英文版), 2024, 33(11): 1012-1024.
[5]	李哲, 罗晓岁, Abid Naeem, 李琼, 张尧, 管咏梅, 陈丽华, 朱卫丰, 金正吉, 冯怡, 明良山. 固体制剂物理结构的研究进展[J]. 中国药学(英文版), 2024, 33(10): 877-905.
[6]	李方存, 张鼎, 李梓, 侯召猛, 陈炜, 陈洁, 胡跃强. 探索干细胞在阿尔茨海默病的研究前景: 2002–2021年文献计量分析[J]. 中国药学(英文版), 2023, 32(10): 813-834.